A Phase 1 Lactation Study in Healthy Adult Lactating Female Subjects One to Six Months Post-Partum to Evaluate the Pharmacokinetics and Safety of Ubrogepant and Atogepant
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Atogepant (Primary) ; Ubrogepant
- Indications Migraine
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 08 Feb 2024 Planned End Date changed from 14 May 2024 to 21 Feb 2024.
- 08 Feb 2024 Planned primary completion date changed from 14 May 2024 to 21 Feb 2024.